ÀÓ»ó½ÃÇè À̹Ì¡ ½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : Á¦°øº°, ¾ç½Äº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)
Clinical Trial Imaging Market Share, Size, Trends, Industry Analysis Report, By Offering; By Modality (Ultrasound, Computed Tomography, X-Ray, Magnetic Resonance Imaging, Others); By Application; By End User; By Region; Segment Forecast, 2024- 2032
»óǰÄÚµå : 1463021
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 114 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,936,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,333,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,730,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠ¿¬±¸¿¡ µû¸£¸é, ¼¼°è ÀÓ»ó½ÃÇè À̹Ì¡ ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 22¾ï 5,012¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

ÀÓ»ó½ÃÇè À̹Ì¡ ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯÀÇ È®»ê¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü Áúȯ, ¾Ï, ½Å°æ Áúȯ µîÀÇ Áúº´ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á¹ý °³¹ß¿¡ ´ëÇÑ ³ë·ÂÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, MRI, CT, PET, ÃÊÀ½ÆÄ µîÀÇ ÀÓ»ó½ÃÇè À̹Ì¡Àº Áúº´ÀÇ ÁøÇà, Ä¡·á ¹ÝÀÀ ¹× ȯÀÚ °á°ú¸¦ Æò°¡ÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ýÀ» Æò°¡Çϱâ À§ÇØ ´õ Å©°í º¹ÀâÇÑ ÀÓ»ó½ÃÇèÀÌ ÁøÇàµÇ´Â °¡¿îµ¥, ¿µ»ó Æò°¡ Ç׸ñÀº Ä¡·á È¿°úÀÇ °´°üÀûÀÎ ÁöÇ¥°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹Àº ÀǾàǰ ½ÂÀÎÀ» À§ÇØ °­·ÂÇÑ ¿µ»ó µ¥ÀÌÅ͸¦ ¿ä±¸Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÓ»ó½ÃÇè À̹Ì¡ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè À̹Ì¡ ½ÃÀåÀº À̹Ì¡ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ »ç¿ë È®´ëµµ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿´Â »ý¹°ÇÐÀû °úÁ¤°ú Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ Á¤·®Àû ÃøÁ¤À» Á¦°øÇÏ¿© ´Ù¾çÇÑ Ä¡·á ¿µ¿ª¿¡¼­ Áúº´ ¸ð´ÏÅ͸µ°ú Ä¡·á Æò°¡¿¡ µµ¿òÀ» ÁÝ´Ï´Ù. Á¤¹ÐÀÇ·á¿Í ¸ÂÃãÄ¡·á¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇÏ¿© Ç¥ÀûÈ­µÈ °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϰí Ä¡·á °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. À̹Ì¡ ±â¼ú°ú ºÐ¼® ¹æ¹ýÀÇ ¹ßÀüÀ¸·Î ÀÓ»ó¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖ´Â À̹Ì¡ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÆøÀÌ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀΰøÁö´É(AI)°ú ±â°èÇнÀ ¾Ë°í¸®ÁòÀÇ ÅëÇÕÀº ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®À» °­È­ÇÏ°í µ¥ÀÌÅÍ Ã³¸®¸¦ °£¼ÒÈ­Çϸç ÀÓ»ó½ÃÇèÀÇ ÀçÇö¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

ÀΰøÁö´É(AI) ±â¼úÀÇ ÅëÇÕÀº ÀÓ»ó½ÃÇè À̹Ì¡ ½ÃÀå¿¡ Å« ±âȸ¸¦ °¡Á®´Ù ÁÙ °ÍÀÔ´Ï´Ù. ¸Ó½Å·¯´× ¹× µö·¯´× ¸ðµ¨°ú °°Àº AI ¾Ë°í¸®ÁòÀº ÀÛ¾÷ ÀÚµ¿È­, ¿À·ù °¨¼Ò, µ¥ÀÌÅÍ Ã³¸® ¼Óµµ Çâ»óÀ¸·Î ÀÇ·á ¿µ»ó ºÐ¼®¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ AI ±â¹Ý À̹ÌÁö ºÐ¼®Àº À̹ÌÁö ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹Ì¹¦ÇÑ º¯È­¸¦ ½Å¼ÓÇÏ°Ô ½Äº°ÇÏ¿© È¿À²¼ºÀ» ³ôÀ̰í, Ä¡·á ¹ÝÀÀÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, AI ±â¹Ý ¼Ö·ç¼ÇÀº ´ë±Ô¸ð ¿µ»ó µ¥ÀÌÅÍ ¼¼Æ®¿¡¼­ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ µµÃâÇÏ¿© ȯÀÚ °èÃþÈ­ ¹× Ä¡·á ¼±Åÿ¡ µµ¿òÀ» ÁÝ´Ï´Ù. È®À强°ú ÀûÀÀ¼ºÀ» ÅëÇØ ÀÓ»ó½ÃÇè ¿î¿µÀ» °£¼ÒÈ­Çϰí ÀÌÇØ°ü°èÀÚ °£ÀÇ Çù¾÷À» ÃËÁøÇÕ´Ï´Ù.

MRI, PET, CT, ±¤ÇÐ À̹Ì¡°ú °°Àº ¼­·Î ´Ù¸¥ ¿µ»ó ¾ç½ÄÀ» °áÇÕÇÏ¿© ¿¬±¸ÀÚµéÀº º¸¿ÏÀûÀÎ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ¾î Áø´ÜÀÇ Á¤È®¼º°ú Ä¡·á Æò°¡¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¸ÖƼ¸ð´Þ À̹Ì¡Àº °³º° ¿µ»ó±â¹ýÀÇ ÇѰ踦 ±Øº¹Çϰí Áúº´ º´Å»ý¸®¿Í Ä¡·á È¿°ú¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀÌÇØ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¿©·¯ ¿µ»ó ¸Å°³º¯¼ö¸¦ °áÇÕÇÏ¿© »õ·Î¿î ¿µ»ó ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½±°Ô °³¹ßÇÒ ¼ö ÀÖ¾î Áúº´ ÁøÇà°ú Ä¡·á È¿°ú¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À̹ÌÁö µî·Ï, À¶ÇÕ ±â¼ú ¹× AI ¾Ë°í¸®ÁòÀÇ ¹ßÀüÀº µ¥ÀÌÅÍ ºÐ¼®ÀÇ È¿À²¼ºÀ» ³ôÀ̰í ÀÓ»ó½ÃÇè ¼³°è ¹× ¼öÇàÀÇ Çõ½ÅÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè À̹Ì¡ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

2023³â¿¡´Â Àüü ÀÓ»ó½ÃÇè °úÁ¤¿¡¼­ ÇʼöÀûÀÎ ¿ªÇÒ, À¯¿¬¼º°ú È®À强, ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ ¿î¿µ À̹Ì¡ ¼­ºñ½º ºÎ¹®ÀÌ »ó´çÇÑ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2023³â ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ ºÐ¾ß´Â Áø´ÜÀÇ ´Ù¾ç¼º, ±¤¹üÀ§ÇÑ ÀÀ¿ë ¹üÀ§, ºü¸¥ À̹ÌÁö ȹµæÀ¸·Î ÀÎÇØ Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2023³â Á¾¾çÇÐ ºÎ¹®Àº Á¾¾çÇÐ ÀÓ»ó½ÃÇèÀÇ ³ôÀº ¹ß»ý·ü, Á¾¾çÇÐ ÀÓ»ó½ÃÇèÀÇ º¹À⼺, Á¾¾çÇÐ ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÇ Áõ°¡·Î ÀÎÇØ Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ ¼ö¿ä´Â ÀǾàǰ °³¹ß ÀÌ´Ï¼ÅÆ¼ºê, Á¤¹Ð ÀÇ·áÀÇ ¹ßÀü, Ä¡·á Çõ½ÅÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2023³â¿¡´Â ºÏ¹Ì°¡ ³ôÀº ¼öÁØÀÇ ÀÇ·á ÀÎÇÁ¶ó, ¸¹Àº ÀÓ»ó½ÃÇè, ´ëÇü Á¦¾à»çÀÇ Á¸Àç·Î ÀÎÇØ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ÀÓ»ó½ÃÇè À̹Ì¡ ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå Á¦°øº° ¼¼°è ½ÃÀå

Á¦6Àå ¸ð´Þ¸®Æ¼º° ¼¼°è ½ÃÀå

Á¦7Àå ¿ëµµº° ¼¼°è ½ÃÀå

Á¦8Àå ÃÖÁ¾»ç¿ëÀÚº° ¼¼°è ½ÃÀå

Á¦9Àå Áö¿ªº° ¼¼°è ½ÃÀå

Á¦10Àå °æÀï »óȲ

Á¦11Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global clinical trial imaging market size is expected to reach USD 2,250.12 Million by 2032, according to a new study by Polaris Market Research. The report "Clinical Trial Imaging Market Share, Size, Trends, Industry Analysis Report, By Offering; By Modality (Ultrasound, Computed Tomography, X-Ray, Magnetic Resonance Imaging, Others); By Application; By End User; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The clinical trial imaging market is propelled by the escalating prevalence of chronic diseases globally. Conditions like cardiovascular diseases, cancer, and neurological disorders are increasing, prompting heightened efforts in therapy development. Clinical trial imaging, utilizing modalities such as MRI, CT, PET, and ultrasound, plays a pivotal role in evaluating disease progression, treatment response, and patient outcomes. With larger and more intricate trials conducted to assess new interventions, imaging endpoints provide objective measures of treatment effects. Regulatory agencies mandate robust imaging data for drug approval, further boosting the demand for clinical trial imaging services.

The clinical trial imaging market is also experiencing growth driven by the expanding applications of imaging biomarkers. These biomarkers offer quantitative measurements of biological processes or treatment responses, aiding in disease monitoring and treatment evaluation across various therapeutic areas. They play a crucial role in precision medicine and personalized therapies, enabling targeted interventions and improving therapeutic outcomes. Advancements in imaging technologies and analytical methods have broadened the range of imaging biomarkers available for clinical use. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms has enhanced biomarker analysis, streamlining data processing and improving reproducibility in clinical trials.

The integration of artificial intelligence (AI) technologies presents significant opportunities in the clinical trial imaging market. AI algorithms, such as machine learning and deep learning models, revolutionize medical image analysis by automating tasks, reducing errors, and expediting data processing. In clinical trials, AI-driven imaging analysis enhances efficiency by rapidly identifying subtle changes in imaging biomarkers, facilitating early treatment response detection. Moreover, AI-based solutions unlock valuable insights from large-scale imaging datasets, aiding in patient stratification and treatment selection. Their scalability and adaptability streamline trial operations, fostering collaboration among stakeholders.

By combining different imaging modalities like MRI, PET, CT, and optical imaging, researchers obtain complementary information, improving diagnostic accuracy and treatment assessment. Multi-modal imaging offers a comprehensive understanding of disease pathology and treatment effects, overcoming the limitations of individual modalities. It facilitates the development of novel imaging biomarkers by combining multiple imaging parameters, enhancing insights into disease progression and treatment response. Furthermore, advancements in image registration, fusion techniques, and AI algorithms streamline data analysis, driving innovation in clinical trial design and execution.

Clinical Trial Imaging Market Report Highlights

In 2023, the operational imaging services segment held considerable revenue share owing to its essential role in entire clinical trial process, flexibility and scalability, and cost-effectiveness.

In 2023, the computed tomography segment held significant revenue share owing to diagnostic versatility, wide application spectrum, and rapid imaging acquisition.

In 2023, the oncology segment held significant revenue share owing to high incidence of oncology trials, complexity of oncology trials, and growing pipeline of oncology drugs.

The demand from pharmaceutical & biotechnology companies is expected to increase during the forecast period owing to drug development initiatives, precision medicine advancements, and therapeutic innovation.

In 2023, North America region accounted for a significant market share due to advanced healthcare infrastructure, high volume of clinical trials, and presence of leading pharmaceutical companies.

The market is highly competitive owing to the existence of market players with a global presence, including BioClinica, BioTelemetry, Inc., Cardiovascular Imaging Technologies, ICON plc, Merge Healthcare, Navitas Clinical Research, Inc, Resonance Health, and WorldCare Clinical among others.

Polaris Market Research has segmented the Clinical Trial Imaging market report based on offering, modality, application, end user, and region:

Clinical Trial Imaging, Offering Outlook (Revenue - USD Million, 2019 - 2032)

Clinical Trial Imaging, Modality Outlook (Revenue - USD Million, 2019 - 2032)

Clinical Trial Imaging, Application Outlook (Revenue - USD Million, 2019 - 2032)

Clinical Trial Imaging, End User Outlook (Revenue - USD Million, 2019 - 2032)

Clinical Trial Imaging, Regional Outlook (Revenue - USD Million, 2019 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Clinical Trial Imaging Market Insights

5. Global Clinical Trial Imaging Market, by Offering

6. Global Clinical Trial Imaging Market, by Modality

7. Global Clinical Trial Imaging Market, by Application

8. Global Clinical Trial Imaging Market, by End User

9. Global Clinical Trial Imaging Market, by Geography

10. Competitive Landscape

11. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â